Testing a hot flash pill for men on prostate cancer therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a non-hormonal pill called fezolinetant to reduce hot flashes in men with prostate cancer who are on hormone therapy. If you have daily, bothersome hot flashes, this study may help you find relief.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man with prostate cancer.
- You are currently on hormone therapy (like Lupron, Degarelix, or orchiectomy) for at least 28 days and plan to stay on it for 42 more days.
- You have had bothersome hot flashes (4 or more per day) for at least a week before starting.
- You are not taking any other hot flash treatments (like estrogen or herbal remedies) during the study.
- You do not have severe liver or kidney problems.
- You are not taking certain medicines that could interact with fezolinetant (like ciprofloxacin or fluvoxamine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
This trial tests if acupuncture can reduce the daily discomfort from hot flashes caused by hormone therapy (androgen deprivation therapy) for prostate cancer. It may help men who are bothered by frequent or intense hot flashes find better relief.
This study follows women in Canada who are starting fezolinetant, a new medication for hot flashes during menopause. Researchers will track how well it works and how you feel while using it in your regular doctor's care.
This trial tests whether a shorter course of hormone therapy, combined with radiation, works as well as a longer course for high-risk prostate cancer. It aims to reduce side effects while keeping the cancer under control.
This trial tests a new medication called fezolinetant to reduce hot flashes (sudden feelings of intense heat) in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of this treatment, and this study aims to see if fezolinetant can help relieve them.
This trial tests a drug called fezolinetant to see if it reduces hot flashes in women with HR+ breast cancer who are on hormone therapy (like tamoxifen or aromatase inhibitors). You need to be postmenopausal and having at least 7 moderate to severe hot flashes a day.
Hear when a new Prostate CA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.